Alvotech lands €100M facility to back 2026 launches
Alvotech, a Reykjavík-based biotech focused on biosimilar medicines, has secured a €100 million senior term loan facility aimed at strengthening liquidity and supporting the company’s strategic priorities through 2026. The financing is designed to help scale manufacturing capacity and reinforce supply chain resilience as the company prepares for several global product launches over the coming year.
The new facility follows a series of balance-sheet actions that have extended the company’s maturity profile and, by management’s account, shifted its financing posture from defensive refinancing to growth enablement. In December 2025, Alvotech placed nearly €92 million in senior unsecured convertible bonds due in 2030. Earlier refinancing steps also pushed major maturities out to 2029, providing additional runway for operational execution.
A higher-cost loan, built for flexibility
According to the company, the €100 million facility replaces an earlier working capital arrangement and provides access to the full amount over a two-year term. The loan is priced at 12.50% interest, payable monthly. While the rate is elevated relative to traditional bank financing, the structure appears designed to prioritize speed and flexibility—features that can be critical for biotech manufacturers managing inventory, batch scheduling, and launch-related working capital needs.
The transaction was led by GoldenTree Asset Management, which has supported the company through prior financing steps. Alvotech said the new setup is intended to simplify capital planning and reduce the need for frequent short-term funding decisions, allowing management to focus on execution.
Why liquidity matters in biosimilars
Commercializing biosimilars is capital intensive even after regulatory approvals. Manufacturers must fund large-scale production runs, maintain quality systems, and build inventory ahead of launch—often while navigating competitive pricing dynamics and tender-based procurement in many markets. For companies pursuing multiple launches in parallel, liquidity and supply chain reliability can be as important as scientific capability.
Scaling manufacturing and shoring up the supply chain
Alvotech said proceeds will be directed toward increasing manufacturing capacity and strengthening its supply chain. The company is preparing for four global product launches through 2026, supported by a network of commercial partners. With access routes established across the US, Europe, Asia, and emerging markets, the company is seeking to convert its development pipeline into sustained commercial performance.
Supply chain resilience has become a central theme for biologics manufacturers, given the complex inputs required for cell culture, purification, fill-and-finish, cold chain logistics, and quality control. Any disruption can delay shipments, reduce batch yields, or complicate regulatory commitments. By investing in capacity and supply chain robustness, Alvotech is aiming to reduce operational bottlenecks that could otherwise constrain revenue during launch windows.
From approvals to pipeline depth
Founded in 2013 by Robert Wessman, Alvotech develops and manufactures biosimilar versions of established biologic medicines. Biologics—including insulin products, vaccines, and monoclonal antibody therapies—have transformed treatment across disease areas, but their high costs can limit access. Biosimilars are intended to improve affordability and availability once reference biologics lose exclusivity.
In a company statement, Robert Wessman, Chairman and CEO of Alvotech, said the new funding reflects continued alignment with its backers and supports its growth agenda. “This €100 million financing underscores the long-term commitment of our financing partners at GoldenTree and their alignment with Alvotech’s strategy,” he said. “Their support strengthens our ability to execute on our growth plans, invest in R&D, and deliver high-quality biosimilars to patients worldwide.”
Alvotech also reiterated the technical definition of its core product category: a biosimilar is a biologic medicine that is highly similar to an already approved reference product, with no clinically meaningful differences, and is produced in living systems.
Commercial footprint and product coverage
Alvotech said five biosimilars are approved and sold across multiple global markets, targeting reference biologics including Humira, Stelara, Eylea, Simponi, and Prolia/Xgeva. These reference products span large therapeutic categories such as autoimmune diseases, ophthalmology, and bone health—areas with significant patient populations and established demand.
Beyond marketed products, the company reported nine disclosed biosimilar candidates across indications including respiratory disease, cancer, osteoporosis, and inflammatory disorders. In total, the company’s R&D engine encompasses around 30 products at various stages of development, signaling a strategy built on breadth of pipeline and repeatable manufacturing execution.
What to watch in 2026
The next year will test whether Alvotech can translate financing and pipeline depth into consistent launch performance. Key milestones will likely include execution of the four planned launches, evidence of stable manufacturing throughput, and progress across late-stage development assets. In biosimilars, market uptake can be shaped by payer policies, substitution rules, tender outcomes, and competitive pricing—factors that often differ significantly by region.
For now, the €100 million facility adds liquidity and extends planning visibility as Alvotech pushes forward with expansion and commercialization in a global biosimilars market that continues to attract intense competition and growing demand for lower-cost biologics.
Related
